Article

Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain.

Covance Market Access Services Inc., 9801 Washingtonian Blvd., 9th Fl., Gaithersburg, MD 20878, USA. .
Journal of managed care pharmacy: JMCP (Impact Factor: 2.68). 10/2012; 18(8):615-26.
Source: PubMed

ABSTRACT Chronic pain is a prevalent condition in the United States. Musculoskeletal pain, including joint and back pain, is the most common type of chronic pain, and many patients with back pain have a neuropathic component. Pain has direct economic consequences. While oxycodone controlled-release (CR) is one of the most widely used oral long-acting opioids for pain, including pain with a neuropathic component, it is often associated with bothersome side effects, resulting in additional medical resource use (MRU) and costs.
To examine the impact on MRU and costs to payers of side effects in patients taking oxycodone CR alone or in combination with other pain medications for noncancer pain (including those with neuropathic pain symptoms).
A nationwide convenience sample of adults in the United States, who participated in a survey research panel and reported current use of oxycodone CR for noncancer pain, completed an online survey between November 2, 2010, and December 13, 2010. Respondents were excluded if they reported current use of other extended-release or long-acting opioid prescription medications. The survey consisted of questions on demographics, clinical characteristics, pain characteristics, experience with pain medication, and MRU associated with side effects. Payer costs were calculated based on the MRU reported by the respondents multiplied by Medicare reimbursement rates for hospitalizations and outpatient visits and average wholesale price (AWP) minus 20% for medications. A subgroup of patients who reported neuropathic pain symptoms also was examined.
After applying the exclusion criteria, 432 respondents completed the survey. Approximately half of the respondents (n = 219; 50.7%) reported neuropathic pain symptoms. The majority of respondents were Caucasian (88.4%) and female (63.7%) with an average age of 41.8 years (14.89). Respondents most frequently reported low back pain (41.2%), followed by osteoarthritis/rheumatoid arthritis (20.4%), neuropathic pain (10.6%), and fibromyalgia (9.0%). Respondents reported having their pain condition for an average of 5.4 (7.42) years. On days when taken, respondents reported a mean oxycodone CR daily dose of 83.3 mg (126.93) taken in an average of 2 doses. Most respondents (82.4%) reported experiencing at least 1 side effect with 77.5% being bothered by at least 1 side effect. The most frequently reported side effects ( greater than 25%) were drowsiness (41.4%), constipation (37.0%), fatigue or daytime sleepiness (36.6%), and dizziness (27.1%). Among respondents who reported being bothered by one or more side effects in the previous month, MRU associated with side effects was reported by 39.1% of respondents and significantly increased as the level of side-effect bother increased from 19.8% among those "A little bit bothered" to 38.4% among those "Bothered" to 61.0% among those "Extremely bothered" (P  less than  0.001). Additionally, total average payer costs (in 2010 dollars) per respondent in the previous month associated with side effects were $238 ($1,159) and also significantly increased as the level of side-effect bother increased from $61 ($512) among those "A little bit bothered" to $238 ($1,160) among those "Bothered" to $425 ($1,561) among those "Extremely bothered" (P  less than  0.001). Results reported in the neuropathic pain subgroup were similar to results reported in the total study sample.
Among adults taking oxycodone CR for chronic noncancer pain (with or without a neuropathic pain component), over three-fourths reported being bothered by side effects. Respondents who reported higher levels of side-effect bother also reported greater MRU, resulting in increased payer costs. The results of this study provide further support of the econo-mic burden to payers associated with opioid-related side effects in patients with chronic noncancer pain, with and without neuropathic pain.

0 Followers
 · 
93 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Osteoarthritis (OA) of the knee is a painful condition affecting ~13% of persons >65 years old. We sought to examine whether the use of opioids in older persons with OA has increased over the past decade and what patient characteristics may correlate with their use.Methods: We assembled national cohorts of individuals with knee OA using data from 2003, 2006, and 2009 waves of the Medicare Beneficiary Survey (MCBS). Survey data contained demographics, health status and prescribed medications linked to Medicare claims. We used multivariate logistic regression to establish whether opioid use changed over time and identify factors associated with greater opioids use. The outcome was defined as receiving ≥1 opioid prescription in the study year.Results: Mean age and sex were similar across years (77 years, 69% females). There was a significant increase in opioid prescribing between 2003 and 2009, with 31% of the patients receiving opioids in 2003, 39% in 2006 and 40% in 2009 (OR 1.5, 95% CI 1.1, 2.0 for 2006 and 2009 compared to 2003). Independent correlates of opioid use across time periods included: female sex (OR 1.5, 95% CI 1.2, 2.0), functional limitation (OR 2.1, 95% CI 1.6, 2.7), poor self-reported health status (OR 1.6, 95% CI 1.2, 2.0), COPD (OR 1.4, 95% CI 1.0, 1.8) and musculoskeletal disease besides OA (OR 1.9, 95% CI 1.2, 2.8).Conclusion: As prevalence and incidence of knee OA continues to increase, the public health impact of greater opioid use should be monitored carefully. © 2014 American College of Rheumatology.
    10/2014; 66(10). DOI:10.1002/acr.22360
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to assess the economic cost of chronic pain among adolescents receiving interdisciplinary pain treatment. Information was gathered from 149 adolescents (ages 10-17) presenting for evaluation and treatment at interdisciplinary pain clinics in the United States. Parents completed a validated measure of family economic attributes, the Client Service Receipt Inventory, to report on health service use and productivity losses due to their child's chronic pain retrospectively over 12 months. Health care costs were calculated by multiplying reported utilization estimates by unit visit costs from the 2010 Medical Expenditure Panel Survey. The estimated mean and median costs per participant were $11,787 and $6,770 respectively. Costs were concentrated in a small group of participants, the top 5 % of those patients incurring the highest costs accounted for 30 % of total costs while the lower 75 % of participants accounted for only 34 % of costs. Total costs to society for adolescents with moderate to severe chronic pain were extrapolated to $19.5 billion annually in the U.S. The cost of childhood chronic pain presents a substantial economic burden to families and society. Future research should focus on predictors of increased health services use and costs in adolescents with chronic pain.
    Journal of Pain 06/2014; DOI:10.1016/j.jpain.2014.06.002 · 4.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We propose a nonparametric framework for voice conversion, that is, exemplar-based sparse representation with residual compensation. In this framework, a spectrogram is reconstructed as a weighted linear combination of speech segments, called exemplars, which span multiple consecutive frames. The linear combination weights are constrained to be sparse to avoid over-smoothing, and high-resolution spectra are employed in the exemplars directly without dimensionality reduction to maintain spectral details. In addition, a spectral compression factor and a residual compensation technique are included in the framework to enhance the conversion performances. We conducted experiments on the VOICES database to compare the proposed method with a large set of state-of-the-art baseline methods, including the maximum likelihood Gaussian mixture model (ML-GMM) with dynamic feature constraint and the partial least squares (PLS) regression based methods. The experimental results show that the objective spectral distortion of ML-GMM is reduced from 5.19 dB to 4.92 dB, and both the subjective mean opinion score and the speaker identification rate are increased from 2.49 and 73.50% to 3.15 and 79.50%, respectively, by the proposed method. The results also show the superiority of our method over PLS-based methods. In addition, the subjective listening tests indicate that the naturalness of the converted speech by our proposed method is comparable with that by the ML-GMM method with global variance constraint.
    10/2014; 22(10):1506-1521. DOI:10.1109/TASLP.2014.2333242

Full-text (2 Sources)

Download
28 Downloads
Available from
May 22, 2014